About The Study: In contrast to the standard of care, only one in four U.S. adolescent residential addiction treatment facilities offered buprenorphine and one in eight offered buprenorphine for ongoing treatment for opioid use disorder. By comparison, nearly two-thirds of adult residential facilities offer buprenorphine.
Authors: Caroline King, Ph.D., M.P.H., of the Oregon Health & Science University School of Medicine in Portland, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.6266)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.6266?guestAccessKey=c84c825c-a2a3-4646-8886-88c5bee75816&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061323
JAMA